<DOC>
	<DOCNO>NCT02537444</DOCNO>
	<brief_summary>To characterize safety efficacy acalabrutinib ( ACP-196 ) monotherapy acalabrutinib plus pembrolizumab combination therapy subject recurrent ovarian cancer</brief_summary>
	<brief_title>Acalabrutinib ( ACP-196 ) Alone Combination With Pembrolizumab Ovarian Cancer ( KEYNOTE191 )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Women ≥ 18 year age . Histologically confirm ovarian epithelial ( include fallopian tube primary peritoneal ) carcinoma . Progression disease recent anticancer treatment . At least 1 prior chemotherapy regimen must include taxane . Platinumsensitive ovarian cancer define recurrence progression disease &gt; 6 AND &lt; 24 month completion recent platinumbased therapy . Measurable disease define RECIST 1.1 . ECOG performance status 0 1 . Completion therapy treatment cancer 2 week start study therapy recover . Evidence platinumrefractory ovarian cancer define recurrence progression first 6 cycle &lt; 6 month begin firstline platinum base chemotherapy . Evidence platinumresistant ovarian cancer define recurrence progression within 6 month complete recent platinumbased therapy . More 3 prior line cytotoxic chemotherapy ovarian cancer . Prior malignancy ( ovarian cancer ) , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year . Breastfeeding pregnant . Known central nervous system metastases and/or carcinomatous meningitis . Subjects active cardiovascular disease medically control myocardial infarction past 6 months.. Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease , partial complete bowel obstruction .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>